Yongin, South Korea — November 3, 2025
GC Biopharma has announced promising Phase 2 clinical trial results for its recombinant anthrax vaccine, BARYTHRAX inj. (GC1109), marking a significant milestone in the global race to enhance biodefense preparedness. The findings, published in the prestigious journal Vaccine, demonstrate that BARYTHRAX is both safe and highly immunogenic, setting a new benchmark in next-generation vaccine development.
Science Significance
In this randomized, double-blind, placebo-controlled Phase 2 study, 240 healthy adults were enrolled across five leading Korean hospitals, including Seoul National University Hospital and The Catholic University of Korea St. Vincent’s Hospital. The trial showed that BARYTHRAX elicited strong antibody responses capable of neutralizing anthrax toxin beyond the pre-defined protective threshold. This confirms robust immunogenicity and supports the vaccine’s ability to offer meaningful protection against anthrax infection.
The vaccine is the world’s first recombinant protein-based anthrax vaccine, utilizing advanced recombinant DNA technology to produce only the Protective Antigen (PA) — the critical target of anthrax immunity. This innovation eliminates the risks associated with live attenuated bacteria, offering a safer and faster-to-manufacture alternative.
Regulatory Significance
The Phase 2 trial, approved by Korea’s Ministry of Food and Drug Safety (MFDS), adheres strictly to Good Clinical Practice (GCP) standards. GC Biopharma’s achievement reinforces South Korea’s GxP leadership and demonstrates the country’s capacity to develop vaccines that meet international regulatory and quality standards.
As Korea’s 39th New Drug and 3rd New Drug Vaccine, BARYTHRAX positions itself as a critical asset in national and global biodefense strategies, aligning with WHO and CDC preparedness priorities for biological threats.
Advertisement
Business Significance
This development strengthens GC Biopharma’s standing as a global innovator in biologics and vaccines. Following its 2024 U.S. launch of Alyglo™ (IVIG), the successful publication of BARYTHRAX data showcases the company’s expanding expertise in protein engineering, vaccine development, and recombinant biologics.
The company’s strategic collaboration with the Korea Disease Control and Prevention Agency (KDCA) further underscores the strength of public-private partnerships in high-impact pharmaceutical innovation. With a proven manufacturing scalability advantage, GC Biopharma is well-positioned to serve international markets and governmental stockpile programs for emergency use.
Patients’ Significance
Anthrax remains a serious zoonotic and bioterrorism-related threat, capable of causing severe respiratory infections when aerosolized. By demonstrating excellent safety—with only mild and temporary adverse reactions such as injection-site pain and fatigue—BARYTHRAX provides a critical safe immunization pathway for both civilian and defense populations.
Dr. Nam Joong Kim, principal investigator from Seoul National University Hospital, highlighted that this success represents “a major step in Korea’s vaccine independence” and paves the way for “safe, rapid-response vaccines against high-risk pathogens.”
Policy Significance
The success of BARYTHRAX aligns with South Korea’s national biosecurity policies and the global One Health initiative, emphasizing preparedness for emerging and re-emerging infectious diseases.
This innovation contributes to regional vaccine sovereignty, reducing dependency on imported biodefense solutions and reinforcing public health resilience under evolving global threat scenarios. Policymakers are likely to view this achievement as a model for local manufacturing capacity-building and public-private R&D collaboration under GxP frameworks.
The publication of BARYTHRAX Phase 2 results marks a transformative moment for GC Biopharma and the broader biopharmaceutical community. As the world’s first recombinant anthrax vaccine, BARYTHRAX combines scientific rigor, regulatory compliance, and manufacturing innovation to deliver a robust tool for global biodefense readiness. With its favorable safety and efficacy data, GC Biopharma is poised to advance toward Phase 3 trials and potential global market authorization, further solidifying its position as a pioneer in vaccine science and public health innovation.
Source : GC Biopharma press release
